The startup develops antibody-based immunotherapeutic products utilizing proprietary technology to create multiple anti-tumor mechanisms for treating gastrointestinal cancers, including those of the colon, stomach, pancreas, liver, and esophagus. This approach addresses the limited treatment options available for patients suffering from these aggressive cancers.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Gastrointestinal cancers, including those of the colon, stomach, pancreas, liver, and esophagus, present limited treatment options, leading to poor outcomes for patients suffering from these aggressive diseases. Current therapies often lack specificity, resulting in significant side effects and limited efficacy in advanced solid tumors.
Solution
ArbeleBio is developing antibody-based immunotherapeutic products that target Cadherin-17 (CDH17), a biomarker highly expressed in gastrointestinal cancers and other solid tumors. The company's proprietary TriAx bispecific antibody platform and antibody-drug conjugates (ADCs) are designed to create multiple anti-tumor mechanisms, including T/NK cell cytotoxicity redirection, immune checkpoint inhibition, and targeted delivery of cytotoxic drugs. ArbeleBio's approach aims to improve treatment precision, minimize off-target effects, and enhance the efficacy of cancer therapies. Additionally, the company is developing advanced cell therapies, including next-generation CAR-T cells, designed to combat solid tumor microenvironments by targeting multiple tumor antigens and reversing tumor immunosuppression.
Target Audience
The primary target audience includes patients with gastrointestinal cancers and other advanced solid tumors, as well as oncologists and medical professionals seeking more effective and targeted treatment options.
Features
- TriAx/Bispecific antibody platform with two novel core structures designed for low antigenicity, stability, and optimal bio-distribution and pharmacokinetics
- Antibody Drug Conjugates (ADCs) developed from a proprietary library of >300 anti-CDH17 monoclonal antibodies
- Next-generation CAR-T cells utilizing non-viral CAR vectors designed to target multiple tumor antigens and reverse tumor immunosuppression
- "AI-CAR" cells that generate an enhanced immune response only when stimulated by tumor cells, functioning as artificial immunosurveillance
- In vitro diagnostics (IVD) solutions for GI cancers, including blood and tissue diagnostics, and point-of-care tests, through its subsidiary Tiberias Technology